The latest price target for Guardant Health (NASDAQ:GH) was reported by Barclays on January 23, 2025. The analyst firm set a price target for $60.00 expecting GH to rise to within 12 months (a possible 36.36% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for Guardant Health (NASDAQ:GH) was provided by Barclays, and Guardant Health initiated their overweight rating.

The last upgrade for Guardant Health Inc happened on June 28, 2024 when Guggenheim raised their price target to $36. Guggenheim previously had a neutral for Guardant Health Inc.

The last downgrade for Guardant Health Inc happened on May 1, 2023 when OTR Global changed their price target from N/A to N/A for Guardant Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Guardant Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Guardant Health was filed on January 23, 2025 so you should expect the next rating to be made available sometime around January 23, 2026.

While ratings are subjective and will change, the latest Guardant Health (GH) rating was a initiated with a price target of $0.00 to $60.00. The current price Guardant Health (GH) is trading at is $44.00, which is within the analyst’s predicted range.